Lyme Disease Diagnostic Test
Diagnosis of Lyme borreliosis
Pre-commercial/Regulatory ReviewActive
Key Facts
Indication
Diagnosis of Lyme borreliosis
Phase
Pre-commercial/Regulatory Review
Status
Active
Company
About En Carta Diagnostics
En Carta Diagnostics is a Paris-based diagnostic company pioneering novel testing solutions for infectious diseases. Its flagship program is a Lyme disease test that has received FDA Breakthrough Device Designation, indicating its potential to address a significant unmet clinical need. The company is in a pre-commercial stage, building a waitlist for its lead product while likely advancing its underlying technology platform. En Carta operates in the high-growth global infectious disease diagnostics market, targeting improved early detection and diagnosis.
View full company profile